Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16892217 | 0.86 | ALDH1A1 (0.60) | ALDH1A1TDP1HSD17B10MAPK1MAOB | |
| SCHEMBL6165864 | 0.84 | ALDH1A1 (0.78) | ALDH1A1TDP1HSD17B10MAPK1CYP3A4 | |
| SCHEMBL6897658 | 0.81 | ALDH1A1 (0.58) | ALDH1A1TDP1HSD17B10MAPK1CYP3A4 | |
| Piperonal SCHEMBL20184609 | 0.81 | ALDH1A1 (0.72) | ALDH1A1TDP1HSD17B10CYP3A4ATM | |
| SCHEMBL16892161 | 0.80 | RAB9A (0.68) | ALDH1A1TDP1HSD17B10MAOBNPC1 | |
| Piperonal SCHEMBL29411164 | 0.80 | ALDH1A1 (1.00) | ALDH1A1TDP1HSD17B10MAPK1CYP3A4 | |
| Piperonal SCHEMBL1864802 | 0.80 | ALDH1A1 (1.00) | ALDH1A1TDP1HSD17B10MAPK1CYP3A4 | |
| Piperonal SCHEMBL29318 | 0.80 | ALDH1A1 (1.00) | ALDH1A1TDP1HSD17B10MAPK1CYP3A4 | |
| SCHEMBL27824359 | 0.80 | ALDH1A1 (0.58) | ALDH1A1TDP1HSD17B10MAPK1CYP3A4 | |
| SCHEMBL18415547 | 0.79 | ALDH1A1 (0.71) | ALDH1A1MAPK1MAOBCASP3SENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078057-B2 | Process for producing nanometer particles by fluid bed spray-drying | KERKHOF NICHOLAS J | 2006-07-18 | — | — | US | claimed |
| EP-1568690-A1 | The use of carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones as sodium channel blockers | Euro-Celtique S.A. (LU) | 2005-08-31 | — | — | EP | claimed |
| EP-1239844-B1 | PROCESS FOR PRODUCING NANOMETER PARTICLES BY FLUID BED SPRAY-DRYING | KERKHOF NICHOLAS J (US) | 2005-06-08 | — | — | EP | claimed |
| EP-0986540-B1 | THE USE OF CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AS SODIUM CHANNEL BLOCKERS | EURO CELTIQUE SA (LU) | 2005-02-16 | — | — | EP | claimed |
| US-6696442-B2 | THERAPY OF DISORDER RESPONSIVE TO THE BLOCKADE OF SODIUM CHANNELS IN A MAMMAL SUFFERING THEREFROM BY ADMINISTERING CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES, WHICH ACT AS BLOCKERS OF SODIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2004-02-24 | — | — | US | claimed |
| US-20030225080-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | EURO-CELTIQUES S.A. | 2003-12-04 | — | — | US | claimed |
| US-20030211162-A1 | Process for producing nanometer particles by fluid bed spray-drying | KERKHOF NICHOLAS J (US) | 2003-11-13 | — | — | US | claimed |
| US-6638947-B2 | Blockers of sodium channels; treatment of neuronal damage following global and focal ischemia, treatment or prevention of neurodegenerative conditions, pain | EURO-CELTIQUE S.A. (LU) | 2003-10-28 | — | — | US | claimed |
| US-6613803-B1 | Treating, preventing or ameliorating pain | EURO-CELTIQUE S.A. (LU) | 2003-09-02 | — | — | US | claimed |
| US-20020183321-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-12-05 | — | — | US | claimed |
| EP-1239844-A1 | PROCESS FOR PRODUCING NANOMETER PARTICLES BY FLUID BED SPRAY-DRYING | Kerkhof, Nicholas J. (US) | 2002-09-18 | — | — | EP | claimed |
| US-20020061886-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-05-23 | — | — | US | claimed |
| JP-2001526648-A | — | — | 2001-12-18 | — | — | JP | claimed |
| EP-0986540-A4 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | COCENSYS INC (US) | 2001-07-11 | — | — | EP | claimed |
| WO-2001045674-A1 | PROCESS FOR PRODUCING NANOMETER PARTICLES BY FLUID BED SPRAY-DRYING | COCENSYS, INC. (US) | 2001-06-28 | — | — | WO | claimed |
| WO-2001045677-A1 | PROCESS FOR PRODUCING NANOMETER PARTICLES BY FLUID BED SPRAY-DRYING | KERKHOF NICHOLAS J (US) | 2001-06-28 | — | — | WO | claimed |
| EP-0986540-A1 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | Cocensys, Inc. (US) | 2000-03-22 | — | — | EP | claimed |
| WO-1998047869-A1 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | COCENSYS, INC. (US) | 1998-10-29 | — | — | WO | claimed |
| WO-2015101294-A1 | COMPOUNDS WITH ANALGESIC ACTIVITY AND MEDICAL USE THEREOF | 中国人民解放军军事医学科学院毒物药物研究所 | 2015-07-09 | — | — | WO | disclosed |
| WO-1995012572-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1995-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225080-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, SLC1A1, SOD1 | ALDH1A1 91/4885TDP1 743/4885HSD17B10 701/4885 |
| US-20020061886-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, SLC1A1, SOD1 | ALDH1A1 91/4885TDP1 743/4885HSD17B10 701/4885 |
| US-20020183321-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, CBR1, ALDH1A2 | ALDH1A1 97/4885TDP1 731/4885HSD17B10 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.